Abstract
Abstract 3262
Poster Board III-1
CML pts display a certain degree of clinical heterogeneity that is documented by the varying levels of response to tyrosine kinase inhibitor therapy and is best reflected by the Sokal risk score. Clinical differences must be a sign of some biological heterogeneity the basis of which, however, are still poorly understood. Today many high-throughput assays are available that allow to unravel the complexity of cancer cells in a genome-wide fashion. We have used Human 6.0 SNP Arrays (Affymetrix) to perform high-resolution (<1 kb) karyotyping of DNA samples from 73 newly diagnosed chronic phase CML pts. Median age was 55 years (range, 25–73 years); male to female ratio was 39/34; pts were almost equally distributed by Sokal risk score (low, n=23; intermediate, n= 23 high, n= 27). Of 189 genes known to be implicated in the cellular DNA repair pathways, 135 (71%) were found to map in regions affected by CNAs or copy-neutral LOH (uniparental disomy, UPD) in 44/73 (60%) pts. However, this was markedly more frequent in high and intermediate Sokal risk pts (20/27, 74% and 16/23, 69%, respectively) than in low Sokal risk pts (8/23, 33%), although neither the total number of detected regions of CNAs/UPD per sample nor the QC parameters differ significantly across different risk categories. Regions of CNA involving DNA repair genes ranged from 105 Kb to 1.1 Mb and were either focal lesions involving a part or the whole single gene (17% of cases), or more extensive losses/gains including 2 to 84 genes. Monoallelic deletions were much more frequent than amplifications. Regions of UPD involving DNA repair genes were much larger and ranged from 980 kb to 32 Mb.
The pathways and genes most frequently affected by CNAs or UPD are listed in the Table below:
Base Excision Repair (BER) | ||||
MUTYH | DNA glycosilase | 1p34.1 | loss/upd | 10 pts |
PNKP | Polynucleotide kinase | 19q13.33 | loss | 10 pts |
NEIL1 | DNA glycosilase | 15q24.2 | loss | 7 pts |
POLB | DNA polymerase beta | 8p11.21 | loss/upd | 6 pts |
PCNA | Sliding clamp for DNA polymerases | 20p12.3 | loss | 6 pts |
Mismatch Repair (MMR) | ||||
PMS2L5 | Mut L homolog - mismatch and loop recognition | 7q11.23 | loss/upd | 11 pts |
MSH2 | Mut S homolog - mismatch and loop recognition | 2p21 | loss | 8 pts |
POLD1 | DNA polymerase delta | 19q13.33 | loss | 8 pts |
POLA2 | DNA polymerase alpha, subunit 2 | 2p16.3 | loss/upd | 6 pts |
POLE2 | DNA polymerase epsilon, subunit 2 | 14q21–22 | loss | 5 pts |
Nucleotide Excision Repair (NER) | ||||
ERCC1 | 5’ incision subunit of TFIIH complex | 19q13.32 | loss | 11 pts |
ERCC2 | 5’ to 3’DNA helicase of TFIIH complex | 19q13.32 | loss | 10 pts |
XAB2 | Transcription-coupled NER factor | 19p13.2 | loss/upd | 9 pts |
CDK7 | Kinase subunit of TFIIH complex | 5q13.2 | loss | 7 pts |
RPA4 | Binds damaged DNA in preincision complexes | Xp21.33 | loss/upd | 7 pts |
RPA2 | Binds damaged DNA in preincision complexes | 12q24.31 | loss/upd | 6 pts |
Homologous Recombination (HR) | ||||
RAD51C | Homologous pairing | 17q23.2 | loss/upd | 7 pts |
RAD52 | Accessory factor for recombination | 12p13.33 | loss | 7 pts |
XRCC2 | DNA break and crosslink repair | 7q36.1 | loss | 5 pts |
Non-Homologous End Joining (NHEJ) | ||||
PRKDC | DNA-dependent protein kinase, catalytic subunit | 8q11.21 | loss/upd | 5 pts |
DCLRE1C | Artemis nuclease | 10p13 | loss | 5 pts |
REV7 | DNA polymerase zeta, subunit | 1p36.22 | gain | 5 pts |
Other genes involved in DNA replication/repair/modification or chromatin remodeling | ||||
CHAF1A | Chromatin assembly factor | 19p13.3 | loss | 15 pts |
RECQL5 | DNA helicase | 17q25.1 | loss/upd | 11 pts |
RAD9B | PCNA-like DNA damage sensor | 12q24.11 | loss/upd | 10 pts |
CHEK2 | DNA-damage checkpoint | 22q12.1 | loss/upd | 8 pts |
RAD17 | RFC-like DNA damage sensor | 5q13.2 | loss | 6 pts |
TREX1 | DNAase III exonuclease | 3p12.31 | loss/upd | 6 pts |
Base Excision Repair (BER) | ||||
MUTYH | DNA glycosilase | 1p34.1 | loss/upd | 10 pts |
PNKP | Polynucleotide kinase | 19q13.33 | loss | 10 pts |
NEIL1 | DNA glycosilase | 15q24.2 | loss | 7 pts |
POLB | DNA polymerase beta | 8p11.21 | loss/upd | 6 pts |
PCNA | Sliding clamp for DNA polymerases | 20p12.3 | loss | 6 pts |
Mismatch Repair (MMR) | ||||
PMS2L5 | Mut L homolog - mismatch and loop recognition | 7q11.23 | loss/upd | 11 pts |
MSH2 | Mut S homolog - mismatch and loop recognition | 2p21 | loss | 8 pts |
POLD1 | DNA polymerase delta | 19q13.33 | loss | 8 pts |
POLA2 | DNA polymerase alpha, subunit 2 | 2p16.3 | loss/upd | 6 pts |
POLE2 | DNA polymerase epsilon, subunit 2 | 14q21–22 | loss | 5 pts |
Nucleotide Excision Repair (NER) | ||||
ERCC1 | 5’ incision subunit of TFIIH complex | 19q13.32 | loss | 11 pts |
ERCC2 | 5’ to 3’DNA helicase of TFIIH complex | 19q13.32 | loss | 10 pts |
XAB2 | Transcription-coupled NER factor | 19p13.2 | loss/upd | 9 pts |
CDK7 | Kinase subunit of TFIIH complex | 5q13.2 | loss | 7 pts |
RPA4 | Binds damaged DNA in preincision complexes | Xp21.33 | loss/upd | 7 pts |
RPA2 | Binds damaged DNA in preincision complexes | 12q24.31 | loss/upd | 6 pts |
Homologous Recombination (HR) | ||||
RAD51C | Homologous pairing | 17q23.2 | loss/upd | 7 pts |
RAD52 | Accessory factor for recombination | 12p13.33 | loss | 7 pts |
XRCC2 | DNA break and crosslink repair | 7q36.1 | loss | 5 pts |
Non-Homologous End Joining (NHEJ) | ||||
PRKDC | DNA-dependent protein kinase, catalytic subunit | 8q11.21 | loss/upd | 5 pts |
DCLRE1C | Artemis nuclease | 10p13 | loss | 5 pts |
REV7 | DNA polymerase zeta, subunit | 1p36.22 | gain | 5 pts |
Other genes involved in DNA replication/repair/modification or chromatin remodeling | ||||
CHAF1A | Chromatin assembly factor | 19p13.3 | loss | 15 pts |
RECQL5 | DNA helicase | 17q25.1 | loss/upd | 11 pts |
RAD9B | PCNA-like DNA damage sensor | 12q24.11 | loss/upd | 10 pts |
CHEK2 | DNA-damage checkpoint | 22q12.1 | loss/upd | 8 pts |
RAD17 | RFC-like DNA damage sensor | 5q13.2 | loss | 6 pts |
TREX1 | DNAase III exonuclease | 3p12.31 | loss/upd | 6 pts |
For some genes (e.g., RAD52), the monoallelic deletion we detected was found to translate into reduced mRNA expression, observation that was also independently confirmed in an additional group of high/intermediate versus low Sokal risk pts. In all the 44 pts, multiple pathways and multiple genes within the same pathway were affected, supporting the hypothesis that the lesions we detected might actually have consequences on DNA integrity despite the known partial functional redundancy of pathways and effectors. For many of the genes identified in this screen, activating or inactivating mutations are known to occur, and together with overexpression or haploinsufficiency, have been linked to a mutator phenotype in several malignant conditions. We are currently investigating whether this may be the case also in CML. Supported by European LeukemiaNet, AIL, AIRC, PRIN, Fondazione del Monte di Bologna e Ravenna.
Baccarani:Novartis: Honoraria, Research Funding, Speakers Bureau; Bristol-Myers Squibb: Honoraria, Research Funding, Speakers Bureau.
Author notes
Asterisk with author names denotes non-ASH members.